Lobaplatin or Cisplatin Plus Etoposide for Treating Extensive Stage Small Cell Lung Cancer

Abstract

Objective: To observe the short-term therapeutic effect, adverse reactions and hospitalization conditions of lobaplatin plus etoposide (EL) and cisplatin plus etoposide (EP) for advanced small cell lung cancer (SCLC). Methods: A total of 46 patients with advanced SCLC were randomized into EL (23 patients) and EP (23 patients) groups. The two groups were treated for two cycles of 21 days. Short-term therapeutic effects, adverse reactions and hospitalization conditions were evaluated for the two groups after two cycles. Results: The EL and EP groups did not differ substantial in objective response rate, hospital stay, or rate of leukocyte and platelet decrease. In the two groups, NSE (neuron-specific enolization enzyme) was reduced significantly after chemotherapy, but CEA (carcinoembryonic antigen) and CYFRA21 (cytokeratin 19 fragment) were not different between the two groups. In the EL group, the incidence of gastrointestinal reaction was reduced significantly and hospitalization cost was significantly increased. Conclusion: EL and EP for the same period of SCLC is safe and effective chemotherapy regimens, EL group medical expenses increased significantly, but the digestive tract reaction decreased significantly.